On behalf of our Company and the Board of Directors, it is a great pleasure to formally welcome Walter and Denis to our team.
VANCOUVER, BC (PRWEB)
June 28, 2021
Medipure Holdings Inc. held its Annual General Meeting on June 9th, 2021, and today announced that Walter Berukoff, President of Red Lion Management, Chairman and CEO of Lion One Metals Ltd., and Denis J. Gallagher, CEO of Economic Transformation Technologies (ETT) and Chairman of BOLD Capital Group, LLC, were formally voted on and unanimously approved by voting shareholders to join the Company’s Board of Directors.
“On behalf of our Company and the Board of Directors, it is a great pleasure to formally welcome Walter and Denis to our team,” stated Boris Weiss, Chairman and CEO of Medipure Holdings Inc. “Walter has played an impactful role and his expertise will be key to our efforts moving forward. Denis has already brought so much to Medipure with his leadership and accomplished public markets experience. We look forward to him continuing to leverage his expertise with our go-public plans and furthering the growth of the Company.”
Mr. Berukoff founded Red Lion Management Ltd., a global family office, in 1971 and has since amassed considerable holdings in real estate and manufacturing facilities. He has taken an active role in developing and turning around business enterprises throughout the Americas, Europe, Africa, and Asia, and has been an international advisor in Cuba, Argentina, and Peru, providing strategic input to national infrastructures. Having raised more than five billion dollars in shareholder value for global mining and real estate projects throughout his career, Mr. Berukoff has earned a solid reputation as a leading Canadian operator and financier.
Prior to being appointed CEO of ETT earlier this year, Mr. Gallagher was Founder, Chairman and CEO of Student Transportation Inc., a publicly listed transportation and logistics company based in Toronto and New Jersey. The company was listed on the Toronto Stock Exchange in 2004 and became dual-listed in 2011 on NASDAQ and in April 2018 the company took part in a go-private sale to its largest shareholder, the Caisse de dépôt et placement in Quebec. In addition to his leadership skills, Mr. Gallagher’s experience in business development, corporate governance and accessing public capital markets will assist with the future growth of Medipure.
Medipure is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms.
Cautionary Note Regarding Forward Looking Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward- looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur, negative of these terms, or other similar expressions intended to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to the expected medical benefits, viability, safety, efficacy, and dosing. Forward-looking statements are based on certain assumptions made by the Company in light of the experience and perception of historical trends, current conditions, and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties, and assumptions, readers should not place undue reliance on these forward-looking statements. Whether actual results, performance, or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions, and other factors, including the inherent uncertainty of product development; our patent application may not be successful, third-party claims relating to misappropriation of their intellectual property; and our reliance on current early-stage research regarding the medical benefits, viability, safety, efficacy, and dosing. If any of these risks or uncertainties materialize, or if assumptions underlying the forward-looking statements prove incorrect, actual results might vary materially from those anticipated in the forward-looking statements.
Information contained in forward-looking statements in this news release is provided as of the date of this news release, and we disclaim any obligation to update any forward-looking statements, whether as a result of new information or future events or results, except to the extent required by applicable securities laws. Accordingly, readers should not place undue reliance on forward-looking statements, or the information contained in those statements.
Share article on social media or email: